<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834167</url>
  </required_header>
  <id_info>
    <org_study_id>UTAR-45-2021</org_study_id>
    <nct_id>NCT04834167</nct_id>
  </id_info>
  <brief_title>OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women</brief_title>
  <official_title>OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Tunku Abdul Rahman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Tunku Abdul Rahman</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OneDoc Picopulse™ is a radiopulse technology beauty grade device invented for treating&#xD;
      melasma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a new attempt to evaluate the effectiveness of OneDoc PicopulseTM in treating melasma&#xD;
      among women of childbearing age in Klang Valley, Malaysia. This pilot feasibility study&#xD;
      protocol is to access feasibility of the OneDoc Picopulse™ in the future definitive trial.&#xD;
      The findings of this study would justify OneDoc Picopulse™ as one of the promising&#xD;
      alternative treatment for melasma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptability of the treatment</measure>
    <time_frame>One month</time_frame>
    <description>Short Assessment of Patient Satisfaction (SAPS) questionnaire with additional Qualitative data collection; The score range for SAPS is from 0 (extremely dissatisfied) to 28 (extremely satisfied)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the recruitment and measurement tools</measure>
    <time_frame>Pre-treatment, two weeks and one month</time_frame>
    <description>Number of patients referred from OneDoc and eligible for screening&#xD;
Number of patients recruited&#xD;
Follow-up response rates (2 weeks and 1 month follow-ups)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>five months</time_frame>
    <description>Number of treatments attended</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melasma</measure>
    <time_frame>Through study completion, an average of 24 weeks</time_frame>
    <description>Melasma Severity Index (MSI) and by observation; MSI score ranges from 0 (no melasma) to 64 (severe melasma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patients</measure>
    <time_frame>Pre-treatment, two weeks and one month post-treatment</time_frame>
    <description>Melasma Quality of Life Scale (MELASQOL) score ranges from 10 to 70; Higher the score, worse is the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>immediately after and before each subsequent treatment</time_frame>
    <description>Incidence and severity of side effects caused by treatments</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Skin Diseases</condition>
  <condition>Skin Disorder</condition>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive ten picopulse treatments for bi-monthly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OneDoc Picopulse</intervention_name>
    <description>Eligible patients will proceed to receive skin cleansing prior to OneDoc Picopulse treatment. After the cleansing, the patients will receive OneDoc Picopulse treatment for 15 mins. Patients will receive ten picopulse treatments for bi-monthly.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women presenting dermal melasma with Fritzpatrick skin type III to V&#xD;
&#xD;
          -  Malaysian citizen&#xD;
&#xD;
          -  Agreed to participate&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had a laser procedure, phototherapy therapy, peel, oral therapy, topical&#xD;
             treatment or used lightening creams in the treatment area within the past 6 months.&#xD;
&#xD;
          -  Patients with pregnancy, lactating, active dermatitis, had a history of&#xD;
             immunosuppression/immune deficiency disorders&#xD;
&#xD;
          -  Patients who photosensitivity or taking drugs known to induce photosensitivity,&#xD;
&#xD;
          -  Patients that have been exposed to severe sun exposure, having severe epidermal&#xD;
             injury, allergy and sensitivity&#xD;
&#xD;
          -  Patients who could not attend follow-up treatments&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Mooi Lim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Tunku Abdul Rahman</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Mooi Lim, PhD</last_name>
    <phone>60390860288</phone>
    <email>ymlim@utar.edu.my</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chai Nien Foo, PhD</last_name>
    <phone>60390860288</phone>
    <email>foocn@utar.edu.my</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Amini F, Thazin Oo NM, Okechukwu PN, Seghayat MS, Ng ESC. Polymorphisms in P53 and VEGFA genes in different subtypes of periorbital hyperpigmentation in a Malaysian Chinese population. Australas J Dermatol. 2019 May;60(2):e99-e104. doi: 10.1111/ajd.12918. Epub 2018 Sep 14.</citation>
    <PMID>30215845</PMID>
  </results_reference>
  <results_reference>
    <citation>Chalermchai T, Rummaneethorn P. Effects of a fractional picosecond 1,064 nm laser for the treatment of dermal and mixed type melasma. J Cosmet Laser Ther. 2018 Jun;20(3):134-139. doi: 10.1080/14764172.2017.1376098. Epub 2017 Dec 4.</citation>
    <PMID>29020467</PMID>
  </results_reference>
  <results_reference>
    <citation>Labadie JG, Krunic AL. Long pulsed dye laser with a back-to-back double-pulse technique and compression for the treatment of epidermal pigmented lesions. Lasers Surg Med. 2019 Feb;51(2):136-140. doi: 10.1002/lsm.23009. Epub 2018 Oct 15.</citation>
    <PMID>30320904</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Tunku Abdul Rahman</investigator_affiliation>
    <investigator_full_name>Yang Mooi Lim</investigator_full_name>
    <investigator_title>Professor Dr. Lim Yang Mooi</investigator_title>
  </responsible_party>
  <keyword>Melasma</keyword>
  <keyword>Skin treatment</keyword>
  <keyword>Picopulse</keyword>
  <keyword>Malaysian women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

